Brian Adams - Sep 3, 2025 Form 4 Insider Report for Kymera Therapeutics, Inc. (KYMR)

Role: Chief Legal Officer
Signature: /s/ Bruce Jacobs, as Attorney-in-Fact
Stock symbol: KYMR
Transactions as of: Sep 3, 2025
Transactions value $: $0
Form type: 4
Date filed: 9/3/2025, 05:05 PM
Previous filing: Jul 30, 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Adams Brian	Chief Legal Officer	C/O KYMERA THERAPEUTICS, INC., 500 NORTH BEACON STREET, 4TH FLOOR, WATERTOWN	/s/ Bruce Jacobs, as Attorney-in-Fact	2025-09-03	0001636994

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	KYMR	Common Stock	Award	$0	+52.5K		$0.00	52.5K	Sep 3, 2025	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	KYMR	Stock Option (Right to Buy)	Award	$0	+105K		$0.00	105K	Sep 3, 2025	Common Stock	105K	$43.30	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock upon vesting and settlement. The RSUs shall vest in four equal annual installments following September 3, 2025, subject to the reporting person's continued employment through each vesting date.
F2	Twenty-five percent (25%) of the shares underlying this stock option shall vest on September 3, 2026, with the remainder vesting in thirty-six (36) equal monthly installments thereafter, subject to the reporting person's continued employment through each vesting date.